Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 10/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4609109 | 0.89 | PGR (0.49) | PGRKDM4ECA1CA2CA9 | |
| SCHEMBL4624052 | 0.82 | PGR (0.49) | PGRKDM4ECA1CA2CA9 | |
| SCHEMBL4609839 | 0.74 | PGR (0.61) | PGRKDM4ECA1CA2CA9 | |
| SCHEMBL4608270 | 0.71 | PGR (0.62) | PGRKDM4EFPR2PROKR1 | |
| SCHEMBL508893 | 0.70 | KCNH2 (0.38) | PGRLMNA | |
| SCHEMBL509319 | 0.70 | KCNH2 (0.38) | PGR | |
| SCHEMBL4608810 | 0.68 | PGR (0.34) | PGRKDM4ESCN9ALMNA | |
| SCHEMBL4114649 | 0.66 | PGR (0.50) | PGRKDM4ELMNA | |
| SCHEMBL4609190 | 0.65 | PGR (0.53) | PGRCA1CA2CA9CA12 | |
| SCHEMBL10250582 | 0.64 | KCNH2 (0.31) | PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948615-B1 | Pyrazole derivatives useful for the treatment of gynaecological diseases | PFIZER LTD (GB) | 2011-12-14 | — | — | EP | claimed |
| US-7425569-B2 | 1H-pyrazoles useful in therapy | PFIZER INC (US) | 2008-09-16 | — | — | US | claimed |
| US-20080085919-A1 | 1H-Pyrazoles Useful In Therapy | BRADLEY PAUL A | 2008-04-10 | — | — | US | claimed |
| US-7309712-B2 | 1H-pyrazoles useful in therapy | PFIZER LIMITED (GB) | 2007-12-18 | — | — | US | claimed |
| US-20070105909-A1 | Compounds useful in therapy | PFIZER INC. | 2007-05-10 | — | — | US | claimed |
| EP-1948615-B1 | Pyrazole derivatives useful for the treatment of gynaecological diseases | PFIZER LTD (GB) | 2011-12-14 | — | — | EP | disclosed |
| US-7309712-B2 | 1H-pyrazoles useful in therapy | PFIZER LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| US-20070105909-A1 | Compounds useful in therapy | PFIZER INC. | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105909-A1 | Compounds useful in therapy | GNRHR, OPRK1, CBR3 | PGR 155/4885KDM4E 1423/4885CA1 1956/4885 |
| US-20080085919-A1 | 1H-Pyrazoles Useful In Therapy | CBR3, GNRHR, RXFP3 | PGR 87/4885KDM4E 2056/4885CA1 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.